65,437 trials
Prostate Adenocarcinoma · PSA Progression · Recurrent Prostate Carcinoma
Primary: Number of Lesions Detected by Investigational Imaging Agent — 31; 20 lesions
Metastatic Castration Resistant Prostate Cancer · Metastatic Cancer · Solid Tumor
Primary: The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment. — 2; 0 participants
Keratoconus, Unstable · Collagen Crosslinking · Postoperative Pain
Primary: Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3…
HIV/AIDS · Adherence, Medication · Drug Use
Primary: Baseline TFV (Tenofovir) Levels in Plasma
Anterior Cruciate Ligament Injuries · Exercise · Cartilage, Articular
Primary: T1rho Relaxation Times in the Medial Femoral Condyle at Baseline — 53.48 ms
Pelvic Floor Disorders
Primary: Changes of Levator Hiatal Area During Valsava — 20.64; 20.35; 22.35; 21.41 Cm2 — p=0.086
Psoriasis
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Midazolam — 4.07; 4.46 Nanograms per millilitre (ng/mL)
Thrombocytopenia
Primary: Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study — 80.0; 60.0; 58.3; 91.7 percentage of participants
Atelectasis · Pulmonary Complications
Primary: Significant Postoperative Pulmonary Complication Incidence. — 48; 33; 162; 176 Participants
Acute Ischemic Stroke
Primary: Percentage of Participants With Successful Revascularization — 98.0 Percentage of participants
Healthy
Primary: Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs) — 1; 3; 4; 1 participants
Breast Cancer Metastatic
Primary: Progression Free Rate at Month 6 — 93.4; 91.3 Percentage of participants
Aortic Dissection
Primary: The Difference Concentrations of ANG II in Serum Between Patients With and Without Postoperative Hypoxemia. — 100; 78.5 pg / mL
Peripheral T-Cell Lymphoma
Primary: Tumor Response (Central Assessment) — 19.3; 45.6 percentage of participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab — 12.7; 11.6 micrograms per milliliter (ug/mL)